Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05572268Phase 3Unknown

EFFICACY OF ANSA (Experimental Drug) & CRAN MAX (Control Drug) SACHET

Role: lead

NCT05563064Phase 3Unknown

Effect of Herbal Formulation on Thrombocytes Count

Role: lead

NCT03506919Phase 1Unknown

Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis

Role: lead

NCT02642250Phase 2Completed

Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea

Role: lead

All 4 trials loaded